Analyzing Avalo Therapeutics (NASDAQ:AVTX) and Opus Genetics (NASDAQ:IRD)

Opus Genetics (NASDAQ:IRD) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, dividends, valuation, risk and institutional ownership.

Profitability

This table compares Opus Genetics and Avalo Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-1,091.82%	N/A	-150.13%
Avalo Therapeutics	N/A	-58.03%	-48.22%

Institutional and Insider Ownership

15.0% of Opus Genetics shares are held by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are held by institutional investors. 11.7% of Opus Genetics shares are held by company insiders. Comparatively, 4.5% of Avalo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Opus Genetics and Avalo Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20 million	23.34	-$49.59 million	($1.35)	-2.97
Avalo Therapeutics	$60,000.00	5,926.11	-$78.26 million	($4.37)	-1.52

Opus Genetics has higher revenue and earnings than Avalo Therapeutics. Opus Genetics is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Opus Genetics has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 0.75, indicating that its stock price is 25% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Opus Genetics and Avalo Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	1	1	16	1	2.89
Avalo Therapeutics	1	2	11	0	2.71

Opus Genetics currently has a consensus target price of $12.71, indicating a potential upside of 217.06%. Avalo Therapeutics has a consensus target price of $37.00, indicating a potential upside of 458.07%. Given Avalo Therapeutics’ higher possible upside, analysts plainly believe Avalo Therapeutics is more favorable than Opus Genetics.

Summary

Opus Genetics beats Avalo Therapeutics on 9 of the 14 factors compared between the two stocks.

About Opus Genetics

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

About Avalo Therapeutics

Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.